COVID-19 Prevention
AstraZeneca to Supply Canada with 100,000 Doses of Evusheld, a Long-Acting Antibody Combination for the Prevention of COVID-19
AstraZeneca Canada
PR-M02-22-21Feb 23, 2022
Clinical Data
New Fasenra® Data from the Meltemi Extension Trial Confirm Long-term Safety and Efficacy in Severe Eosinophilic Asthma for up to Five Years
AstraZeneca
PR-M06-21-004Jun 02, 2021
Drug Approval
Farxiga Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type-2 Diabetes
AstraZeneca
PR-M05-21-004-1000May 06, 2021
COVID-19 Vaccine
HALIX Signs Agreement With AstraZeneca For Commercial Manufacture Of COVID-19 Vaccine
HALIX
PR-M11-20-031Dec 10, 2020
COVID-19 Long-Acting AntiBody (LAAB) Combination AZD7442 Rapidly Advances into Phase III Clinical Trials
AstraZeneca
PR-M10-20-07Oct 13, 2020
Breakthrough Therapy
Farxiga Granted Breakthrough Therapy Designation in U.S. for Chronic Kidney Disease
AstraZeneca
PR-M10-20-02Oct 02, 2020
AstraZeneca, Oxford SARS-CoV-2 Vaccine Trials Temporarily Paused
AstraZeneca
PR-M09-20-NI-11Sep 09, 2020
COVID-19 Vaccine
Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222
Catalent
PR-M08-20-NI-41Aug 26, 2020
Clinical Trials
AstraZeneca Initiates Phase I Clinical Trial Initiated for Monoclonal Antibody Combination for COVID-19
AstraZeneca
PR-M08-20-NI-38Aug 25, 2020
Flu Vaccine
AstraZeneca Ships FLUMIST QUADRIVALENT Vaccine in the U.S. for 2020-2021 Flu Season
AstraZeneca
PR-M08-20-NI-25Aug 14, 2020
COVID-19 Vaccine
AstraZeneca Signs COVID-19 Vaccine Deal with Chinese Company
AstraZeneca
PR-M08-20-NI-12Aug 07, 2020
Collaboration
AstraZeneca and Daiichi Sankyo Enter Collaboration to Develop and Commercialize New Antibody Drug Conjugate
AstraZeneca
PR-M07-20-NI-41Jul 27, 2020
Approval
AstraZeneca's Breztri Aerosphere Approved in the US for the Maintenance Treatment of COPD
AstraZeneca
PR-M07-20-NI-37Jul 24, 2020
COVID-19 Vaccine
SGS Signs Analytical Testing Agreement with AstraZeneca for COVID-19 Vaccine Candidate
SGS Life Science Services
PR-M07-20-NI-28Jul 17, 2020
Clinical Results
AstraZeneca's Drug Significantly Reduces the Rate of the Composite of Stroke and Death in Patients
AstraZeneca
PR-M07-20-NI-027Jul 16, 2020
Vaccine Manufacturing
Daiichi Sankyo Announces Start of Discussions with AstraZeneca Regarding Supply in Japan of Novel Coronavirus Vaccine
Daiichi-Sankyo
PR-M06-20-NI-036-1473Jun 26, 2020
Oncology
Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukemia in Two Trials
AstraZeneca
PR-M06-20-NI-019-1504Jun 12, 2020
Partnership
ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring Assays for Minimal Residual Disease
ArcherDX
PR-M06-20-NI-011Jun 08, 2020
Collaboration
AstraZeneca to Discover and Develop Novel Therapies Targeting RNA-Modifying Proteins in Oncology Collaboration with Accent Therapeutics
AstraZeneca
PR-M06-20-NI-005Jun 04, 2020
Oncology
AstraZeneca Collaborates with ArcherDX to Use Personalized Cancer Assays to Detect Minimal Residual Disease in Lung Cancer Trials
AstraZeneca
PR-M05-20-NI-044May 29, 2020